Loading...
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook, G Ashcroft, A Cairns, D Williams, C Brown, J Cavenagh, J Snowden, J Parrish, C Yong, K Cavet, James
Cook, G
Ashcroft, A
Cairns, D
Williams, C
Brown, J
Cavenagh, J
Snowden, J
Parrish, C
Yong, K
Cavet, James
Citations
Altmetric:
Abstract
The Myeloma X trial previously reported improved durability of response (time to disease progression) in patients with relapsed multiple myeloma with salvage autologous stem-cell transplantation (ASCT) compared with oral cyclophosphamide in patients with multiple myeloma relapsing after a first ASCT. We report the final overall survival results of the trial.
Description
Date
2016-07
Publisher
Collections
Keywords
Type
Article
Citation
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. 2016, 3 (7):e340-51 Lancet Haematol